Immunology superstar Dupixent, which first brought Regeneron and Sanofi together in 2007, has entered its megablockbuster era ...

Cendakimab fell short of the bar. The antibody hits IL-13, one of the interleukins targeted by Regeneron and Sanofi’s ...

Regeneron Pharmaceuticals beat fourth-quarter sales and profit estimates on Tuesday, on continuing demand for its eczema ...

The success of dupilumab, marketed by Sanofi under the name Dupixent, is evident in its remarkable $13 billion global sales achievement in 2024, marking a significant milestone for the company.

The use of Dupixent in AD has set a high benchmark for competitors within the space. However, despite its market leadership, Hudson has noted the need for increased competition, which is essential ...

Sanofi’s jump in earnings comes with an increased emphasis on R&D and vaccines, plus an eye cast toward M&A to shore up its pipeline.

Anti-inflammatory Dupixent's sales are up 15%, and a midstage trial of treatment for muscle loss caused by obesity drugs is fully enrolled Regeneron Pharmaceuticals Inc.'s stock rose 4.9% Tuesday ...

One primary reason is the strong performance and potential of Dupixent, which is expected to partially counterbalance the uncertainties surrounding Eylea. The expected growth in Dupixent’s ...

Long-term use of oral steroids may have serious side ... The Food and Drug Administration (FDA) has approved the biologic drug dupilumab (Dupixent). Doctors prescribe it for people with moderate ...

Furthermore, the successful launch of Dupixent for chronic obstructive pulmonary disease (COPD) has garnered significant coverage from top commercial and Medicare payers, indicating strong market ...

Despite Eylea's market challenges, Dupixent's strong performance and future potential in COPD, along with a robust pipeline, position Regeneron for recovery in 2025. Regeneron's solid financials ...